RR-A3: Triple Agonist Research Guide

RR-A3 (LY3437943) is a novel triple-receptor agonist that simultaneously activates GLP-1, GIP, and Glucagon receptors—a first-in-class approach to metabolic research. - Composition: 39-amino acid peptide - Conjugation: C20 fatty diacid moiety for albumin binding - Half-life: Approximately 6 days - Administration: Once-weekly subcutaneous injection | Receptor | Primary Effects | |----------|-----------------| | GLP-1 | Reduces appetite, slows gastric emptying, enhances insulin secretion | | GIP | Stimulates insulin release, reduces appetite, impacts fat metabolism | | Glucagon | Increases energy expenditure, promotes lipolysis, enhances thermogenesis | Compared to natural hormones: - 0.3× potency at glucagon receptors - 0.4× potency at GLP-1 receptors - 8.9× more potent at GIP receptors Phase 2 research demonstrated: - Significant reductions in body weight at 48 weeks - Improvements in metabolic markers - Enhanced glycemic control indicators - Weight effects not yet plateaued at study completion In subjects with elevated liver fat: - Substantial liver fat reduction (up to 82%) - Potential implications for metabolic liver disease Studies show improvements in: - Non-HDL cholesterol - ApoB levels - Triglycerides - ApoC-III - Triglyceride-rich lipoprotein particles | Drug Class | Mechanism | Approach | |------------|-----------|----------| | GLP-1 Agonist | Single receptor | Incretin effect | | Dual GIP/GLP-1 | Two receptors | Enhanced incretin | | Triple Agonist | Three receptors | Incretin + energy expenditure | The addition of glucagon receptor agonism provides: - Increased energy expenditure - Enhanced lipolysis and fatty acid oxidation - Direct liver metabolism targeting (liver is rich in glucagon receptors) - Potential complementary effects on thermogenesis Common observations include: - Gastrointestinal effects (nausea, primarily dose-dependent) - Generally mild-to-moderate in severity - Higher incidence at escalating doses Ongoing research areas: - Long-term metabolic outcomes - Cardiovascular effects - Liver disease applications - Expanded population studies Note: This compound is in clinical development and for research purposes only.